¼¼°èÀÇ ºÎºñµ¿¿° Ä¡·á ½ÃÀå
Sinusitis Treatment
»óǰÄÚµå : 1796015
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 480 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,206,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,620,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ºÎºñµ¿¿° Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 40¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 29¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ºÎºñµ¿¿° Ä¡·á ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 5.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 40¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±Þ¼º ºÎºñµ¿¿° ÁúȯÀº CAGR 6.6%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 26¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾Æ±Þ¼º ºÎºñµ¿¿° Áúȯ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 3.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 7¾ï 9,100¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ºÎºñµ¿¿° Ä¡·á ½ÃÀåÀº 2024³â¿¡ 7¾ï 9,100¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 9.1%·Î 2030³â±îÁö 8¾ï 2,040¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.7%¿Í 5.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ºÎºñµ¿¿° Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ºÎºñµ¿¿°ÀÌ ¼¼°è ÁÖ¿ä °Ç°­ ¹®Á¦·Î ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

ºÎºñµ¿ÀÇ ¿°ÁõÀ» Ư¡À¸·Î ÇÏ´Â ºÎºñµ¿¿°Àº ³ôÀº À¯º´·ü, »îÀÇ Áú¿¡ ¹ÌÄ¡´Â ¿µÇâ, ÀÇ·á ½Ã½ºÅÛ¿¡ ´ëÇÑ °æÁ¦Àû ºÎ´ãÀ¸·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î ½É°¢ÇÑ °Ç°­ ¹®Á¦·Î Àνĵǰí ÀÖ½À´Ï´Ù. ºÎºñµ¿¿°Àº ºÎºñµ¿ÀÌ ºÎ¾î¿À¸£°Å³ª °¨¿°µÇ¾î ÄÚ¸·Èû, ¾È¸éÅëÁõ, ¾Ð¹Ú°¨, Èİ¢ÀúÇÏ µîÀÇ Áõ»óÀ» À¯¹ßÇÏ´Â ÁúȯÀÔ´Ï´Ù. ±Þ¼º ºÎºñµ¿¿°°ú ¸¸¼º ºÎºñµ¿¿°ÀÌ ¸ðµÎ ¸¸¿¬ÇØ ÀÖÀ¸¸ç, ¸¸¼º ºÎºñµ¿¿°Àº Àå±âÀûÀÎ Ä¡·á¿Í Àü¹®ÀÇÀÇ °³ÀÔÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù. È£Èí±â °¨¿°ÁõÀÇ Áõ°¡, ¾Ë·¹¸£±â, ´ë±â¿À¿°, µµ½ÃÈ­ÀÇ ÁøÀüÀÌ ºÎºñµ¿¿° ȯÀÚ Áõ°¡¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ƯÈ÷ Àα¸ ¹ÐÁýµµ°¡ ³ôÀº »ê¾÷Áö¿ª¿¡¼­ ºÎºñµ¿¿° ȯÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ýȰ½À°üÀÇ º¯È­, ´ã¹è ¿¬±â, ¾Ë·¹¸£°Õ, Á÷¾÷¼º ¿À¿°¹°Áú µî ȯ°æ ÀÚ±Ø ¹°ÁúÀÌ ºÎºñµ¿ °Ç°­ ¹®Á¦¸¦ ¾ÇÈ­½Ã۰í ÀÖ½À´Ï´Ù. õ½Ä, ¸é¿ª °áÇÌ µî ±âÀúÁúȯÀ» ¾Î°í Àִ ȯÀÚµéÀº ƯÈ÷ ¿µÇâÀ» ¹Þ±â ½±½À´Ï´Ù. ºÎºñµ¿¿°Àº ½ÅüÀû ºÒÆíÇÔÀ» À¯¹ßÇÒ »Ó¸¸ ¾Æ´Ï¶ó ÇÇ·Î, ¼ö¸é Àå¾Ö, »ý»ê¼º ÀúÇÏ·Î À̾îÁö±â ¶§¹®¿¡ È¿°úÀûÀ̰í Á¢±ÙÇϱ⠽¬¿î Ä¡·á¹ýÀÇ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. ºÎºñµ¿¿°ÀÇ ¹ÌÄ¡·á ¹× °ü¸® ¹ÌÈíÀ¸·Î ÀÎÇÑ Àå±âÀûÀÎ ÇÕº´Áõ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Àü ¼¼°èÀûÀ¸·Î Á¶±â Áø´Ü ¹× Á¾ÇÕÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÇ·á ½Ã½ºÅÛ°ú Á¦¾à»çµéÀº ºÎºñµ¿ °ü·Ã Ä¡·á ¹× ¿¬±¸¸¦ ¿ì¼±¼øÀ§·Î »ï°í ÀÖ½À´Ï´Ù.

ÀÇÇÐÀÇ ¹ßÀüÀ¸·Î ºÎºñµ¿¿° Ä¡·áÀÇ »óȲÀº ¾î¶»°Ô º¯È­Çϰí ÀÖÀ»±î?

ºÎºñµ¿¿° Ä¡·á ºÐ¾ß´Â ÀÇÇÐÀÇ ¹ßÀü°ú ÇÔ²² º¸´Ù È¿À²ÀûÀ̰í ȯÀÚ Ä£È­ÀûÀÎ Ä¡·á¹ý ¼±ÅÃÀÌ ´Ã¾î³ª¸é¼­ Å©°Ô ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ±âÁ¸¿¡´Â ºÎºñµ¿¿° Ä¡·á¸¦ À§ÇØ ÄÚ ÃæÇ÷ Á¦°ÅÁ¦, ½Ä¿°¼ö ½ºÇÁ·¹ÀÌ, Ç×È÷½ºÅ¸¹ÎÁ¦, ¼¼±Õ °¨¿°¿¡ ´ëÇÑ Ç×»ýÁ¦ Åõ¿© µîÀÌ ½ÃÇàµÇ¾ú½À´Ï´Ù. ÇÏÁö¸¸ Çö´ë ÀÇÇÐÀº ÃÖ¼Òħ½À ¼ö¼ú, »ý¹°ÇÐÀû Ä¡·á, ÷´Ü Áø´Ü µµ±¸¸¦ µµÀÔÇÏ¿© ºÎºñµ¿¿°À» º¸´Ù È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ±â´É¼º ³»½Ã°æ ºÎºñµ¿ ¼ö¼ú(FESS)Àº ¸¸¼º ºÎºñµ¿¿°À̳ª Àç¹ß¼º ºÎºñµ¿¿°¿¡ ³Î¸® äÅõǰí ÀÖÀ¸¸ç, ±âÁ¸ ºÎºñµ¿ ¼ö¼úº¸´Ù ȯÀÚÀÇ È¸º¹ÀÌ ºü¸£°í ÇÕº´Áõµµ Àû½À´Ï´Ù. dz¼± ºÎºñµ¿ ¼ºÇü¼úµµ ȹ±âÀûÀÎ Ä¡·á¹ýÀ¸·Î, ÀÛÀº dz¼±À» ºÎºñµ¿¿¡ »ðÀÔÇÏ¿© ºÎÇ®·Á¼­ Á¶Á÷À» Àý°³ÇÏÁö ¾Ê°í ¸·Èù ºÎºñµ¿À» Á¦°ÅÇÏ¿© ¿Ü»óÀ̳ª ´Ù¿îŸÀÓÀ» Å©°Ô ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ƯÈ÷ ºñ°­ Æú¸³ ¹× È£»ê±¸¼º ¿°Áõ°ú °ü·ÃµÈ ¸¸¼º ºÎºñµ¿¿° ȯÀÚ¿¡¼­ ´ÜŬ·ÐÇ×ü¿Í °°Àº »ý¹°ÇÐÀû Á¦Á¦ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ±âÁ¸ Ä¡·á¹ýÀ¸·Î È¿°ú¸¦ ¾òÁö ¸øÇÏ´Â °æ¿ì¿¡µµ Ä¡·á È¿°ú¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. CT ½ºÄµ, ºñ³»½Ã°æ °Ë»ç µî ¿µ»ó Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î Áø´ÜÀÇ Á¤È®µµ°¡ ³ô¾ÆÁ® °³Àκ° ¸ÂÃã Ä¡·á °èȹÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, ¹Ì»ý¹° ±â¹Ý Ä¡·á¿Í ¸é¿ªÁ¶ÀýÁ¦ ¿¬±¸´Â Ä¡·á ÀúÇ×¼º »ç·Ê¿¡ ´ëÇÑ À¯¸ÁÇÑ ´ë¾ÈÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î Ä¡·áÀÇ ÆÐ·¯´ÙÀÓÀÌ Áõ»ó ¾ïÁ¦¿¡¼­ ±Ùº»ÀûÀÎ ¿øÀÎ ÇØ°á·Î ÀüȯµÇ¾î ÀÓ»óÀÇ¿¡°Ô ºÎºñµ¿¿°À» º¸´Ù È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ´Â ´Ù¾çÇÑ ¼ö´ÜÀÌ Á¦°øµÇ°í ÀÖ½À´Ï´Ù.

ºÎºñµ¿¿° Ä¡·á ¼ö¿ä¸¦ ÁÖµµÇϴ ȯÀÚ ºÎ¹®°ú ÇコÄÉ¾î ½ÃÀåÀº?

ºÎºñµ¿¿° Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ´Ù¾çÇÑ È¯ÀÚ ºÎ¹®°ú Áö¿ª ½ÃÀå¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖÀ¸¸ç, °¢°¢ÀÌ ÀÌ ÇコÄÉ¾î ºÐ¾ßÀÇ ¼¼°è È®Àå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸¸¼º È£Èí±âÁúȯÀ» ¾Î°í ÀÖ´Â ¼ºÀÎ, ¾Ë·¹¸£±â°¡ ÀÖ´Â »ç¶÷, °í³óµµ ¿À¿°¿¡ ³ëÃâµÈ µµ½Ã °ÅÁÖÀÚ´Â ºÎºñµ¿¿°ÀÇ Á¤±âÀûÀÎ Ä¡·á¸¦ ÇÊ¿ä·Î ÇÏ´Â ÁÖ¿ä ±×·ì Áß ÇϳªÀÔ´Ï´Ù. ¼Ò¾Æ°ú ȯÀÚµµ Áõ°¡ÇÏ´Â Ãß¼¼·Î ºÎºñµ¿ ¹Ì¹ß´Þ·Î »ó±âµµ °¨¿°ÀÌ ÀæÀº À¯¾ÆµéÀÌ ¸¹ÀÌ ¾Î°í ÀÖ½À´Ï´Ù. ¸é¿ª·Â ÀúÇÏ¿Í ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) µîÀ» µ¿¹ÝÇÑ ³ëÀε鵵 Àå±âÀûÀÎ ºÎºñµ¿ Ä¡·á°¡ ÇÊ¿äÇÑ Ãë¾à °èÃþÀÔ´Ï´Ù. Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ÀÇ·á ÀÎÇÁ¶óÀÇ ¼±Áø¼º, ³ôÀº ÀÎÁöµµ, Àü¹®ÀÇ¿¡ ´ëÇÑ Á¢±Ù¼º È®»êÀ¸·Î ºÎºñµ¿¿° Ä¡·áÀÇ º¸±ÞÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. À¯·´ÀÌ ±Ù¼ÒÇÑ Â÷ÀÌ·Î ±× µÚ¸¦ ÀÕ°í Àִµ¥, ÀÌ´Â °øÁߺ¸°Ç ³ë·Â°ú º¸Çè Áö¿øÀÌ Á¶±â Áø´Ü°ú Ä¡·á Áö¼Ó¿¡ ±â¿©Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â ¿À¿°µµ Áõ°¡, µµ½Ã °ú¹ÐÈ­, ÀÇ·áºñ ÁöÃâ Áõ°¡·Î ÀÎÇØ ºÎºñµ¿ °ü·Ã Áúȯ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í ¾ÆÇÁ¸®Ä«ÀÇ ½ÅÈï±¹ ½ÃÀåÀº À̺ñÀÎÈİú ¼­ºñ½º È®´ë¿Í ÀÏÂ÷ Áø·á¸Á Á¤ºñ¿¡ ÈûÀÔ¾î Á¡Â÷ ȸº¹¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á ¶ÇÇÑ ¿ø°ÝÁöÀÇ È¯ÀÚ¿Í À̺ñÀÎÈİú Àü¹®ÀǸ¦ Àû½Ã¿¡ ¿¬°áÇÏ¿© º¸´Ù ³ÐÀº ¹üÀ§ÀÇ Áø·á¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÀÌó·³ ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º Á¦°øÀÚ ±â¹ÝÀÌ È®´ëµÊ¿¡ µû¶ó ºÎºñµ¿¿°À» °ü¸®ÇÏ°í ¿ÏÈ­Çϱâ À§ÇÑ ÀǾàǰ°ú ¼ö¼úÀû ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¼¼°è ºÎºñµ¿¿° Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?

¼¼°è ºÎºñµ¿¿° Ä¡·á ½ÃÀåÀº ºÎºñµ¿¿° °ü¸® ¹× ´ëó ¹æ¹ýÀ» À籸¼ºÇÏ´Â ÀÇ·áÀû, °æÁ¦Àû, »çȸÀû ¿äÀÎÀÇ ÁýÇÕÀ¸·Î ÀÎÇØ °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Áúº´ À¯º´·üÀÇ Áõ°¡¿Í ȯÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó, ´õ ¸¹Àº »ç¶÷µéÀÌ ½ÃÁß¿¡¼­ ÆÇ¸ÅµÇ´Â Ä¡·áÁ¦¿¡ ÀÇÁ¸Çϰųª Áõ»óÀ» ¹«½ÃÇÏÁö ¾Ê°í ÀÇ·áÀû °³ÀÔÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ¼±Áø±¹°ú ½ÅÈï±¹ ½ÃÀå ¸ðµÎ ÀǷẸÇèÀÌ È®´ëµÇ¸é¼­ ºÎºñµ¿¿° Áø´Ü, 󹿾à, ¼ö¼ú Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ºñ°­¿Ü¿ë ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å, º´¿ë¿ä¹ý, »ý¹°ÇÐÀû Á¦Á¦ÀÇ °³¹ß µî ÀǾàǰÀÇ Çõ½ÅÀº ȯÀڵ鿡°Ô º¸´Ù È¿°úÀûÀÌ°í Æí¸®ÇÑ Ä¡·á ¿É¼ÇÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ õ½ÄÀ̳ª ¾Ë·¹¸£±â¸¦ µ¿¹ÝÇÑ ¸¸¼º ºÎºñµ¿¿°¿¡ ´ëÇÑ ÀÓ»ó½ÃÇè°ú ½Å¾à ½ÂÀÎÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ³»½Ã°æ°ú ºÎºñµ¿ ÃÔ¿µÀÇ È°¿ë¼ºÀ» Æ÷ÇÔÇÑ º´¿ø ¹× ¿Ü·¡ Ä¡·áÀÇ ¹ßÀüÀº Ä¡·áÀÇ Á¤È®¼º°ú ȯÀÚ °á°ú¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Ç×°ø±â ÀÌ¿ë Áõ°¡, ½Ç³» °ø±â ¿À¿°, ¿¡¾îÄÁ º¸±Þ µî »ýȰ½À°üÀÌ ºÎºñµ¿ °Ç°­ ¹®Á¦¸¦ ºÎÃß±â°í ÀÖ¾î ´ëÀÀ °¡´ÉÇÑ È¯ÀÚÃþÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, À̺ñÀÎÈİú Àü¹®ÀÇ, ÀÏÂ÷ Áø·á ÀÇ»ç, ¸é¿ªÇÐ Àü¹®ÀÇÀÇ ÇùÁøÀ¸·Î Ä¡·áÀÇ Áú°ú Àå±âÀûÀÎ °á°ú¸¦ Çâ»ó½ÃŰ´Â ´ÙÇÐÁ¦Àû Á¢±ÙÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ªÇÐÀº ÀüüÀûÀ¸·Î Çõ½Å, Á¢±Ù¼º, °³ÀÎÈ­µÈ Ä¡·á ¼Ö·ç¼Ç¿¡ ÃÊÁ¡À» ¸ÂÃá ºÎºñµ¿¿° Ä¡·á ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Áúȯ(±Þ¼º ºÎºñµ¿¿° Áúȯ, ¾Æ±Þ¼º ºÎºñµ¿¿° Áúȯ, ¸¸¼º ºÎºñµ¿¿° Áúȯ), Ä¡·á(ÁøÅëÁ¦ Ä¡·á, Ç×»ýÁ¦ Ä¡·á, Ç×È÷½ºÅ¸¹ÎÁ¦ Ä¡·á, ¿Ü°ú Ä¡·á, ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å Ä¡·á, ±âŸ Ä¡·á), Åõ¿© °æ·Î(±¹¼Ò Åõ¿©, ºñ°­ Åõ¿©, °æ±¸ Åõ¿©, ÁÖ»çÁ¦ Åõ¿©), À¯Åë ä³Î(¿Â¶óÀÎ À¯Åë ä³Î, ¼Ò¸Å ¾à±¹, º´¿ø ¾à±¹)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Sinusitis Treatment Market to Reach US$4.0 Billion by 2030

The global market for Sinusitis Treatment estimated at US$2.9 Billion in the year 2024, is expected to reach US$4.0 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Acute Sinusitis Disease, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Sub-Acute Sinusitis Disease segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$791.0 Million While China is Forecast to Grow at 9.1% CAGR

The Sinusitis Treatment market in the U.S. is estimated at US$791.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$820.4 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Sinusitis Treatment Market - Key Trends & Drivers Summarized

Why Is Sinusitis Gaining Attention as a Major Global Health Concern?

Sinusitis, characterized by the inflammation of the sinuses, is increasingly being recognized as a significant health issue worldwide due to its high prevalence, impact on quality of life, and economic burden on healthcare systems. Affecting millions of people each year, sinusitis occurs when the sinus cavities become swollen or infected, leading to symptoms such as nasal congestion, facial pain, pressure, and reduced sense of smell. Both acute and chronic forms of the condition are widespread, with chronic sinusitis often requiring prolonged treatment and specialist intervention. The growing incidence of respiratory infections, allergies, air pollution, and rising urbanization has contributed to the increase in sinusitis cases, especially in densely populated and industrialized regions. Furthermore, lifestyle changes and environmental irritants such as cigarette smoke, allergens, and occupational pollutants continue to exacerbate sinus health problems. Patients with underlying conditions like asthma or immunodeficiencies are particularly susceptible. The condition not only causes physical discomfort but also contributes to fatigue, sleep disturbances, and reduced productivity, underlining the need for effective and accessible treatment options. As awareness grows about the long-term complications of untreated or poorly managed sinusitis, demand for early diagnosis and comprehensive treatment is increasing globally, prompting healthcare systems and pharmaceutical companies to prioritize sinus-related therapies and research.

How Are Medical Advancements Transforming the Landscape of Sinusitis Treatment?

The field of sinusitis treatment has evolved considerably, with medical advancements leading to more targeted, efficient, and patient-friendly therapeutic options. Traditionally, treatment for sinusitis included nasal decongestants, saline sprays, antihistamines, and courses of antibiotics for bacterial infections. However, modern medicine is now incorporating minimally invasive surgical techniques, biologic therapies, and advanced diagnostic tools to manage the condition more effectively. Functional endoscopic sinus surgery (FESS) has become a widely adopted procedure for chronic and recurrent sinusitis, offering patients faster recovery and fewer complications than traditional sinus surgeries. Balloon sinuplasty is another breakthrough, where a small balloon is inserted into the sinus passage and inflated to clear blockages without cutting tissues, greatly reducing trauma and downtime. The use of biologics such as monoclonal antibodies is gaining momentum, especially for patients with chronic sinusitis linked to nasal polyps or eosinophilic inflammation, providing relief where conventional therapies fail. Technological improvements in imaging, such as CT scans and nasal endoscopy, are enhancing diagnostic accuracy and enabling personalized treatment plans. Furthermore, research into microbiome-based therapies and immunomodulators is offering promising alternatives for treatment-resistant cases. These advancements are collectively shifting the treatment paradigm from symptom suppression to root-cause resolution, empowering clinicians with a broader arsenal of tools to manage sinusitis more effectively.

Which Patient Segments and Healthcare Markets Are Driving Demand for Sinusitis Treatment?

The growing demand for sinusitis treatment is being fueled by diverse patient segments and geographic markets, each contributing to the global expansion of this healthcare domain. Adults with chronic respiratory conditions, individuals with allergies, and urban dwellers exposed to high pollution levels are among the key groups seeking regular treatment for sinusitis. Pediatric cases are also on the rise, with young children often affected due to underdeveloped sinuses and frequent upper respiratory infections. The elderly population, who may suffer from weakened immune systems or coexisting conditions like chronic obstructive pulmonary disease (COPD), represent another vulnerable group requiring long-term sinus care. Regionally, North America leads in sinusitis treatment adoption due to advanced healthcare infrastructure, high awareness levels, and widespread access to specialist care. Europe follows closely, with public health initiatives and insurance support contributing to early diagnosis and treatment adherence. In Asia-Pacific, rising pollution levels, urban overcrowding, and growing healthcare expenditure are driving increased attention to sinus-related ailments. Developing markets in Latin America and Africa are gradually catching up, supported by expanding ENT services and improved primary care networks. Telemedicine is also enabling broader reach, connecting patients in remote areas with ENT specialists for timely consultations. This expanding base of patients and healthcare providers is reinforcing the demand for both pharmaceutical and surgical solutions to manage and mitigate sinusitis.

What Key Factors Are Supporting Growth in the Sinusitis Treatment Market Globally?

The global sinusitis treatment market is experiencing strong growth due to a convergence of medical, economic, and societal factors that are reshaping how the condition is managed and addressed. Rising disease prevalence, coupled with growing patient awareness, is pushing more individuals to seek medical intervention rather than relying on over-the-counter remedies or ignoring symptoms. The expansion of health insurance coverage in both developed and emerging markets is improving access to diagnostics, prescription medications, and surgical treatments for sinusitis. Pharmaceutical innovation, particularly in the development of topical nasal corticosteroids, combination therapies, and biologics, is providing patients with more effective and convenient treatment options. Increasing investment in research and development is fueling clinical trials and novel drug approvals, especially for chronic cases and sinusitis linked to comorbid conditions like asthma or allergies. Hospital and outpatient care advancements, including the availability of endoscopic tools and sinus imaging, are enhancing treatment precision and patient outcomes. Lifestyle factors such as increased air travel, indoor air pollution, and the widespread use of air conditioning are contributing to sinus health challenges, thereby expanding the addressable patient base. Finally, collaboration between ENT specialists, primary care physicians, and immunologists is fostering a multidisciplinary approach that enhances care quality and long-term results. These dynamics collectively support the continued growth of the sinusitis treatment market, with a focus on innovation, accessibility, and personalized care solutions.

SCOPE OF STUDY:

The report analyzes the Sinusitis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease (Acute Sinusitis Disease, Sub-Acute Sinusitis Disease, Chronic Sinusitis Disease); Treatment (Analgesics Treatment, Antibiotics Treatment, Antihistamines Treatment, Surgery Treatment, Corticosteroids Treatment, Other Treatments); Administration Route (Topical Administration, Nasal Administration, Oral Administration, Injectable Administration); Distribution Channel (Online Distribution Channel, Retail Pharmacies, Hospital Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â